Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US

Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US

ABSTRACTBackground Cell-based quadrivalent influenza vaccines (QIVc) can increase effectiveness against seasonal influenza by avoiding mismatch from egg adaption of vaccine viruses. This study evaluates the population-level cost-effectiveness and impacts on health outcomes of QIVc versus an egg-base...

Full description

Bibliographic Details
Main Authors: Stephen I. Pelton, Joaquin F. Mould-Quevedo, Van Hung Nguyen
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Expert Review of Vaccines
Subjects:
influenza vaccine
cost-effectiveness
children
cell-based vaccines
vaccine effectiveness
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2023.2295014

Internet

https://www.tandfonline.com/doi/10.1080/14760584.2023.2295014

Similar Items